Alain Vergnenegre (Alain Vergnenègre)

Publication Activity (10 Years)

Years Active: 2018-2020
Publications (10 Years): 5

Top Topics

Small Cell Lung Cancer

Radiation Induced

Tyrosine Kinase

Top Venues

Expert review of pharmacoeconomics & outcomes research

Cancer management and research

Expert review of anticancer therapy

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Alain Vergnenegre, Christos Chouaid
Economic analyses of immune-checkpoint inhibitors to treat lung cancer. Expert review of pharmacoeconomics & outcomes research 21 (3) (2020)
Alain Vergnenegre, Margaux Geier, Florian Guisier, Regine Lamy, Bénédicte Comet, Gwenaelle Le Garff, Pascal Do, Henri Janicot, Hugues Morel, Chantal Decroisette, Michel Andre, Lionel Falchero, Nicolas Paleiron, Isabelle Monnet, null null
Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04). Cancer medicine 9 (2) (2019)
Alain Vergnenegre, Victor Basse, Gwenaelle Le Garff, Olivier Bylicki, Catherine Dubos-Arvis, Bénédicte Comet, Marie Marcq, Jacques Le Treut, Jean-Bernard Auliac, Anne Madroszyk, Gislaine Fraboulet, Jacky Crequit, Pascal Thomas, Nicolas Paleiron, Isabelle Monnet, null null
Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01). Cancer management and research 11 (2019)
Paul Lesueur, Isabelle Martel-Laffay, Alexandre Escande, Manon Kissel, Chrystel Locher, Radj Gervais, Roland Schott, Alain Vergnenegre, Christos Chouaid
Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review. Expert review of anticancer therapy 18 (11) (2018)
Alain Vergnenegre, Christos Chouaid
Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC). Expert review of pharmacoeconomics & outcomes research 18 (5) (2018)